Physician profile
Alan D Kritz
NPI 1508813155
$58,300.37
in general payments reported to CMS, 2019-2025
16 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,469 · 2020: $6,211 · 2021: $9,203 · 2022: $18K · 2023: $16K · 2024: $631 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $712 · Consulting Fee: $600 · Travel and Lodging: $205 · Education: $25.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,983.00 |
| Food and Beverage | $711.91 |
| Consulting Fee | $600.00 |
| Travel and Lodging | $204.62 |
| Education | $25.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34,970.03 | 2022-2025 | Reblozyl, Pomalyst |
| Celgene Corporation | $13,820.47 | 2019-2024 | Reblozyl |
| Verastem, INC. | $3,457.67 | 2019 | |
| Genentech USA, INC. | $2,115.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,925.00 | 2020 | |
| Seagen INC. | $1,375.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $124.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $114.96 | 2024 | Onivyde |
| Jazz Pharmaceuticals INC. | $104.40 | 2019 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Janssen Biotech, INC. | $73.87 | 2024 | Tecvayli, Darzalex |
| Genentech, INC. | $47.95 | 2020 | |
| Tempus Ai, INC | $43.13 | 2024 | Xt Cdx |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Pfizer INC. | $11.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.